Abstract
Cardiovascular disease is the leading cause of major morbidity and mortality in patients with type 2 diabetes. The recent focus on the apparent lack of cardiovascular benefit associated with glucose-lowering strategies has overshadowed the importance of targeting dyslipidemia for cardiovascular prevention in patients with diabetes. While lowering low-density lipoprotein (LDL) cholesterol is beneficial, diabetes is also characterized by hypertriglyceridemia, low levels of high-density lipoproteHDL-cholesterol and abundant levels of small, dense LDL particles. Accordingly, these factors represent additional targets for therapeutic modification in order to achieve more effective reductions in cardiovascular risk.
| Original language | English |
|---|---|
| Pages (from-to) | 40-45 |
| Number of pages | 6 |
| Journal | US Endocrinology |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Aug 2011 |
| Externally published | Yes |
Keywords
- Diabetes mellitus
- Diabetic dyslipidemia
- Hypertriglyceridemia
- Insulin resistance
- LDL-cholesterol-lowering therapy
- Low HDL-cholesterol
- Statin